摘要：Geron公司宣布美国FDA给予端粒酶抑制剂伊美司他(imetelstat)治疗成人复发性/难治性骨髓纤维瘤的快通道审批资格。Ⅱ期临床IMbark试验评价静脉滴注该药4.7或9.4 mg/kg(每3周1次)对中期或高危骨髓纤维瘤、经Janus激酶抑制剂治疗的复发或难治患者的疗效。
注：因版权方要求，不能公开全文，如需全文，请咨询杂志社
热门期刊服务
Journal of Hydrodynamics Journal of Huazhong University of Science and Technology The Journal of China Universities of Posts and Telecommunications Journal of Genetics and Genomics Journal of Iron and Steel Research Journal of Systems Science and Complexity World Journal of Gastroenterology Journal of Computer Science and Technology Applied Mathematics:A Journal of Chinese Universities International Journal of Minerals Metallurgy and Materials International Journal of Mining Science and Technology Journal of Systems Science and Systems Engineering